Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology1, today announced that it has entered a first-of-its-kind agreement to integrate data from its world ...

Future Market Insights (FMI) has revealed an insightful new report showcasing the remarkable growth trajectory of the global patient monitoring devices market. Valued at USD 46.4 million in 2022, the ...

Abbott announced today that it entered a first-of-its-kind agreement to integrate data from its Libre systems into Epic EHR ...

Linking the systems will allow clinicians to view glucose data captured by Libre glucose sensors within Epic’s systems.

Continuous glucose monitoring (CGM ... with normal body mass index using two methods: A CGM device (Abbott Freestyle Libre 2) and the standard finger-prick test for capillary blood glucose.

April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring ... of medical devices for Abbott. "While the integration with Libre data is Abbott's first ...

April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring ... of medical devices for Abbott. "While the integration with Libre data is Abbott's first ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...